Replies to post #705834 on NorthWest Biotherapeutics Inc (NWBO)

[kabunushi]

Blah, blah, blah...This is your most repeated meme and it ignores the simple fact that the vast majority of the 'placebo' group were also treated with DcVax. Also ignored is that DcVax is unusually effective on tumors of the Mesenchymal (MES) phenotype, plus that in recurrent tumors genetic mutation including the well-known Proneural-mesenchymal transition (PMT) has often occurred. "Recurrent GBMs are often characterized by a shift to the MES phenotype." Hence recurrent GBM tumors were often more responsive to DcVax treatment. Because of this and because most of the originally non-DcVax treated patients were treated by DcVax, these thoroughly confounded the ITT analysis.
As LL explained years ago, "We really were comparing 'early DcVax' to 'later DcVax' patients". You will never accept these facts, hence you incorrectly insist that ITT analysis is the most important measure, which it is not. I'm sure you will continue to be in denial when MHRA approves of the MAA. Sorry that your anti-NW bias doesn't allow you to accept the science.

Refer to this AI-generated info coming from Google "gbm tumor phenotype":

Glioblastoma (GBM) is a malignant brain tumor with multiple phenotypes that can be resistant to therapy. These phenotypes include:
Mesenchymal (MES) phenotype
This is the most aggressive and therapy-resistant subtype of GBM. The transition to the MES phenotype can be caused by both genetic alterations within the tumor and microenvironmental factors outside of the tumor. Recurrent GBMs are often characterized by a shift to the MES phenotype.
Proneural-mesenchymal transition (PMT)
This stage occurs during and after CT and is also known as epithelial-mesenchymal transformation (EMT). PMT and EMT are both considered mesenchymal transitions (MT). MT has been associated with malignant phenotypes and chemo-resistant GBM, which can make it difficult to treat the tumor and prevent it from returning.

[drugrunner]

Ex u keep pretending ..

It does work SOLO .. And will be approved DCVAX + SOC

and then per however any doctor wishes per a protocol including and of LL current trials keytruda poly LCIC ETC

[meirluc]

I hate to disappoint you Ex but there were really only 35
placebos in the group of 99 (your so called placebo group).
According to Dr. Liau, of those 35 real placebos, 6-7 dropped
out of the trial we and are therefore left with only 28-29 real placebos
who never received DCVax-L and whose mOS according to Dr. Liau
was dismally short. Most likely those 28-29 progressed and
deteriorated too rapidly for DCVax-L to be of benefit and they
therefore succumbed to the illness relatively quickly.

However, a miracle occurred in that despite the short mOS of
the 28-29 true placebos, the mOS of the entire group of 99 was
even longer than the mOS of the group of 232 treatment patients.
That can only be due to the fact that the 64 crossovers in that group
of 99 had an extremely long mOS that more than made up for the
short mOS of the 28-29 real placebos.

Lesson Learned: 1. The 64 crossover patients lost their placebo status
at the time that they received DCVax-L (after progression) but did extremely
well after receiving DCVax-L .
2. This trial therefore did not have a bona fide placebo group but could have
had one if all or at least most of that group of 99 GBM patients had not
received any DCVax-L throughout the trial.

[Reefrad]

You should contact the esteemed editorial board of Jama and point out their mistake.

lol. What a joke.

[Nemesis18]

It will a sight to behold once the forced Regulatory decision drops, refusing the MAA.

And then the bad news will follow about the 'stealth mode' Direct escapade in the UK☝️🥴

[flipper44]

So, you’re saying near term market approval would shock the world. OK. Thanks